US › Healthcare

Spero Therapeutics Inc (SPRO)

US · Healthcare · Biotechnology

$1.10-2.65%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-9.6M

EPS

$-0.16

EPS estimate

$-0.19

EPS came in at -0.16 against a street estimate of -0.19 — a beat of 15.8%.

Key statistics

Market cap

$64.1M

P/E

7.9

Forward P/E

0.0

P/B

1.67

Book value

$0.76

EPS (TTM)

$0.14

52-week high

$3.08

52-week low

$1.08

50-day MA

$1.19

200-day MA

$2.05

Beta

1.50

Analyst view

Analysts rate Spero Therapeutics Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $5.00.

Shareholding

Insiders

22.66%

Institutions

18.25%

Largest institutional holders

Fund	Stake
GSK PLC	15.78%
Pfizer Inc	4.06%
Vanguard Capital Management, LLC	3.50%
Renaissance Technologies Corp	1.63%
Alphabet Inc	1.53%
Susquehanna International Group, LLP	1.30%
BlackRock Inc	1.02%
Geode Capital Management, LLC	0.97%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Spero Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.